Search

Your search keyword '"Gattei, V"' showing total 688 results
Start Over Author "Gattei, V"
688 results on '"Gattei, V"'

1. IL16 PRODUCTION IS A MECHANISM OF RESISTANCE TO BTK INHIBITORS AND TO R‐CHOP

Author

Arribas, A., primary, Napoli, S., additional, Cascione, L., additional, Sartori, G., additional, Cannas, E., additional, Tarantelli, C., additional, Spriano, F., additional, Gaudio, E., additional, Zucchetto, A., additional, Rossi, F. M., additional, Rinaldi, A., additional, Castro de Moura, M., additional, Jovic, S., additional, Pittau, R. Bordone, additional, Stathis, A., additional, Stussi, G., additional, Gattei, V., additional, Brown, J. R., additional, Esteller, M., additional, Zucca, E., additional, Rossi, D., additional, and Bertoni, F., additional

Published
2023
Full Text
View/download PDF

2. The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia

Author

Morabito, Francesco, Tripepi, G., Mauro, F. R., Laurenti, Luca, Reda, G., Moia, R., Condoluci, A., Vincelli, I., Chiarenza, A., Vigna, E., Martino, E. A., Bruzzese, Maria Antonella, Mezzatesta, S., Laureana, R., Cutrona, G., Di Raimondo, F., Fronza, G., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Olivieri, J., Zaja, F., Rossi, Dario, Gaidano, G., Del Principe, M. I., Ilariucci, F., Del Poeta, G., Ferrarini, M., Neri, A., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Bruzzese A., Rossi F. M., Rossi D., Morabito, Francesco, Tripepi, G., Mauro, F. R., Laurenti, Luca, Reda, G., Moia, R., Condoluci, A., Vincelli, I., Chiarenza, A., Vigna, E., Martino, E. A., Bruzzese, Maria Antonella, Mezzatesta, S., Laureana, R., Cutrona, G., Di Raimondo, F., Fronza, G., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Olivieri, J., Zaja, F., Rossi, Dario, Gaidano, G., Del Principe, M. I., Ilariucci, F., Del Poeta, G., Ferrarini, M., Neri, A., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Bruzzese A., Rossi F. M., and Rossi D.

Abstract

NA

Published
2023

3. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study

Author

Bomben, R., Rossi, Federica Maria, Vit, F., Bittolo, T., Zucchetto, A., Papotti, R., Tissino, E., Pozzo, F., Degan, M., Polesel, J., Bulian, P., Marasca, R., Reda, G., Laurenti, Luca, Olivieri, J., Chiarenza, A., Laureana, R., Postorino, M., Del Principe, M. I., Cuneo, A., Gentile, M., Morabito, Francesco, Fronza, G., Tafuri, A., Zaja, F., Foa, Robin, Di Raimondo, F., Del Poeta, G., Gattei, V., Rossi F. M., Laurenti L. (ORCID:0000-0002-8327-1396), Morabito F., Foa R., Bomben, R., Rossi, Federica Maria, Vit, F., Bittolo, T., Zucchetto, A., Papotti, R., Tissino, E., Pozzo, F., Degan, M., Polesel, J., Bulian, P., Marasca, R., Reda, G., Laurenti, Luca, Olivieri, J., Chiarenza, A., Laureana, R., Postorino, M., Del Principe, M. I., Cuneo, A., Gentile, M., Morabito, Francesco, Fronza, G., Tafuri, A., Zaja, F., Foa, Robin, Di Raimondo, F., Del Poeta, G., Gattei, V., Rossi F. M., Laurenti L. (ORCID:0000-0002-8327-1396), Morabito F., and Foa R.

Abstract

NA

Published
2023

4. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study

Author

Levi, S., Bronstein, Y., Goldschmidt, N., Morabito, Francesco, Ziv-Baran, T., Del Poeta, G., Bairey, O., Del Principe, M. I., Fineman, R., Mauro, F. R., Gutwein, O., Reda, G., Ruchlemer, R., Sportoletti, P., Laurenti, Luca, Shvidel, L., Coscia, M., Tadmor, T., Varettoni, M., Aviv, A., Murru, R., Braester, A., Chiarenza, A., Visentin, A., Pietrasanta, D., Loseto, G., Zucchetto, A., Bomben, R., Olivieri, J., Neri, A., Rossi, Dario, Gaidano, G., Trentin, L., Foa, Robin, Cuneo, A., Perry, C., Gattei, V., Gentile, M., Herishanu, Y., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi D., Foa R., Levi, S., Bronstein, Y., Goldschmidt, N., Morabito, Francesco, Ziv-Baran, T., Del Poeta, G., Bairey, O., Del Principe, M. I., Fineman, R., Mauro, F. R., Gutwein, O., Reda, G., Ruchlemer, R., Sportoletti, P., Laurenti, Luca, Shvidel, L., Coscia, M., Tadmor, T., Varettoni, M., Aviv, A., Murru, R., Braester, A., Chiarenza, A., Visentin, A., Pietrasanta, D., Loseto, G., Zucchetto, A., Bomben, R., Olivieri, J., Neri, A., Rossi, Dario, Gaidano, G., Trentin, L., Foa, Robin, Cuneo, A., Perry, C., Gattei, V., Gentile, M., Herishanu, Y., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi D., and Foa R.

Abstract

NA

Published
2023

5. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study

Author

Autore, Francesco, Innocenti, Idanna, Reda, G., Visentin, A., Vitale, C., Piciocchi, A., Fresa, Alberto, Leone, M. M. A., Farina, L., Quaresmini, G., Barate, C., Giordano, A., Ferrari, A., Angeletti, I., De Paolis, M. R., Malerba, L., Chiurazzi, F., Loseto, G., Catania, G., Sportoletti, P., Scortechini, I., Moia, R., Gentile, M., Rigolin, G. M., Mattiello, V., Gattei, V., Coscia, M., Trentin, L., Foa, Robin, Cuneo, A., Laurenti, Luca, Autore F., Innocenti I., Fresa A., Foa R., Laurenti L. (ORCID:0000-0002-8327-1396), Autore, Francesco, Innocenti, Idanna, Reda, G., Visentin, A., Vitale, C., Piciocchi, A., Fresa, Alberto, Leone, M. M. A., Farina, L., Quaresmini, G., Barate, C., Giordano, A., Ferrari, A., Angeletti, I., De Paolis, M. R., Malerba, L., Chiurazzi, F., Loseto, G., Catania, G., Sportoletti, P., Scortechini, I., Moia, R., Gentile, M., Rigolin, G. M., Mattiello, V., Gattei, V., Coscia, M., Trentin, L., Foa, Robin, Cuneo, A., Laurenti, Luca, Autore F., Innocenti I., Fresa A., Foa R., and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

Clinical or biological parameters useful to predict progression during treatment in real-life setting with ibrutinib, idelalisib and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) are still debated. We conducted a multi-center retrospective study on CLL patients treated with ibrutinib and/or idelalisib who were switched to venetoclax for progression or due to adverse events to identify any clinical and/or biological parameters useful to predict progression during treatment with venetoclax. Of all the 128 evaluable patients, 81 had received ibrutinib prior to switching to venetoclax, 35 had received idelalisib and 12 both. When comparing the three subgroups, we did not notice any statistical difference in terms of clinical or biological features. No variable at baseline and at different time points during the follow-up (at 6, 12, 18 and 24 months) was found to predict progression nor to have significance for Progression Free Survival (PFS) in the ibrutinib group and in the idelalisib group and in subgroups according to the line of treatment. Analyzing the data of the venetoclax treatment, after a median follow up of 14.3 months, median PFS was not reached and estimated 3-year PFS was 54%. Of the 128 patients treated with venetoclax, 28 (22%) experienced progressive disease. At multivariate analysis for predictive factors for progression, lymph node diameter >56.5 mm before starting treatment emerged as an independent risk factor for progression. The lymph node predictive role for progression during venetoclax treatment could be a new parameter that deserves to be investigate in future studies.

Published
2023

6. Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature

Author

Mazzaro, C., Bomben, R., Visentini, M., Gragnani, L., Quartuccio, L., Saccardo, F., Sebastiani, M., Filippini, D., Lauletta, G., Monti, G., and Gattei, V.

Subjects
HBV-related glomerulonephritis, Cancer Research, HBV extra-hepatic manifestations, HBV-related cryoglobulinemia, HBV-related vasculitis, entecavir, hepatitis B virus, tenofovir, Oncology
Abstract

ObjectiveHepatitis B virus (HBV) infection causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Furthermore, about 20% of the patients develop extrahepatic manifestations such as cryoglobulinemic vasculitis (CV), polyarteritis nodosa, non-rheumatoid arthritis, glomerulonephritis and non-Hodgkin lymphoma. This review analyzed literature data on clinical manifestations of HBV-related CV and the impact of antiviral therapy with analoques nucleotide.MethodsA PubMed search was performed to select eligible studies in the literature, up to July 2022.ResultsSome studies have analyzed clinical manifestations in HBV-related CV and have investigated the role of antiviral therapy with nucleotides analogues (NAs). Clinical manifestations of CV vary from mild to moderate (purpura, asthenia and arthralgias) to severe (leg ulcers, peripheral neuropathy, glomerulonephritis, and non-Hodking lymphoma). NAs therapy leads to suppression of HBV-DNA; therefore, it is capable of producing clinical response in the majority of patients with mild to moderate symptoms.ConclusionAntiviral therapy with NAs is the first choice for HBV suppression and control of mild to moderate disease. In severe vasculitis (glomerulonephritis, progressive peripheral neuropathy and leg ulcers), rituximab alone or with plasma-exchange is always indicated in combination with antiviral therapy.

Published
2023

8. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Author

Cuneo, A., Scarfo, L., Reda, G., Varettoni, M., Quaglia, F. M., Marchetti, M., De Paoli, L., Re, F., Pietrasanta, D., Rigolin, G. M., Orsucci, L., Ibatici, A., Gattei, V., Mauro, F. R., Trentin, L., Laurenti, L., Marasca, R., Foa, R., Angeletti, I., Chiurazzi, F., Del Poeta, G., Rosaria De Paolis, M., Farina, L., Ferrari, A., Gentile, M., Gottardi, D., Gozzetti, A., Leone, M., Levato, L., Maccaferri, M., Malerba, L., Motta, M., Murru, R., Nocilli, L., Olivieri, J., Stefoni, V., Cuneo, A., Scarfo', L., Reda, G., Varettoni, M., Quaglia, F. M., Marchetti, M., De Paoli, L., Re, F., Pietrasanta, D., Rigolin, G. M., Orsucci, L., Ibatici, A., Gattei, V., Mauro, F. R., Trentin, L., Laurenti, L., Marasca, R., Foa, R., Angeletti, I., Chiurazzi, F., Del Poeta, G., Rosaria De Paolis, M., Farina, L., Ferrari, A., Gentile, M., Gottardi, D., Gozzetti, A., Leone, M., Levato, L., Maccaferri, M., Malerba, L., Motta, M., Murru, R., Nocilli, L., Olivieri, J., and Stefoni, V.

Subjects
Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Coronavirus Infections, Disease Management, Humans, Italy, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Pandemics, Pneumonia, Viral, SARS-CoV-2, Chronic lymphocytic leukemia, Biochemistry, chemistry.chemical_compound, Pandemic, 80 and over, Viral, Chronic, Disease management (health), Letter to Blood, Leukemia, Hematology, Lymphocytic, Ibrutinib, CLL, COVID-19, Campus CLL, medicine.medical_specialty, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Immunology, Cancer therapy, NO, Internal medicine, medicine, business.industry, B-Cell, Pneumonia, Cell Biology, Campus CLL, medicine.disease, Settore MED/15 - MALATTIE DEL SANGUE, chemistry, business, CLL
Published
2020

12. S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA

Author

Pirosa, M. C., primary, Bruscaggin, A., additional, Terzi di Bergamo, L., additional, Salehi, M., additional, Pini, K., additional, Spina, V., additional, Bocchetta, S., additional, Condoluci, A., additional, Forestieri, G., additional, Piffaretti, D., additional, Marques De Almeida, J., additional, Annunziata, S., additional, Bergesio, F., additional, Borsatti, E., additional, Bulian, P., additional, Chauvie, S., additional, Marco, C., additional, Martina, D. T., additional, Bernhard, G., additional, Kurlapski, M., additional, Moccia, A., additional, Moia, R., additional, Rinaldi, A., additional, Rodari, M., additional, Romanowicz, G., additional, Sacchetti, G. M., additional, Stasia, A., additional, Stathis, A., additional, Stüssi, G., additional, Zangrilli, I., additional, Larocca, L. M., additional, Pinto, A., additional, Santoro, A., additional, Cavalli, F., additional, Zucca, E., additional, Gattei, V., additional, Zaucha, J. M., additional, Carlo-Stella, C., additional, Hohaus, S., additional, Gaidano, G., additional, Ceriani, L., additional, and Rossi, D., additional

Published
2022
Full Text
View/download PDF

13. S136: CONSTITUTIVE VLA-4 ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE OTHER SIDE OF BCR AUTONOMOUS SIGNALING.

Author

Tissino, E., primary, Bomben, R., additional, Maity, P. C., additional, Pozzo, F., additional, Forestieri, G., additional, Nicolò, A., additional, Härzschel, A., additional, Bittolo, T., additional, Rossi, F. M., additional, Datta, M., additional, Zaja, F., additional, Capasso, G., additional, D’Arena, G., additional, Chiarenza, A., additional, Di Raimondo, F., additional, Jumaa, H., additional, Rossi, D., additional, Del Poeta, G., additional, Hartmann, T. N., additional, Zucchetto, A., additional, and Gattei, V., additional

Published
2022
Full Text
View/download PDF

14. P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE

Author

Bomben, R., primary, Rossi, F. M., additional, Vit, F., additional, Bittolo, T., additional, Zucchetto, A., additional, Papotti, R., additional, Tissino, E., additional, Pozzo, F., additional, Degan, M., additional, Zaina, E., additional, Cattarossi, I., additional, Nanni, P., additional, Marasca, R., additional, Reda, G., additional, Laurenti, L., additional, Olivieri, J., additional, Chiarenza, A., additional, Ballotta, L., additional, Cuneo, A., additional, Gentile, M., additional, Morabito, F., additional, Tafuri, A., additional, Zaja, F., additional, Foà, R., additional, Di Raimondo, F., additional, Del Poeta, G., additional, and Gattei, V., additional

Published
2022
Full Text
View/download PDF

15. Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia

Author

Forestieri, G., Terzi di Bergamo, L., Deodato, M., Frustaci, A. M., Moia, R., Deambrogi, C., Rasi, S., Autore, Francesco, Merli, Maria Clara, Mattarucchi, R., Fahrni, G., Scarfo', L., Gussetti, D., Bulian, P., Zanatta, A., Spina, V., Bruscaggin, A., Pini, K., Piffaretti, D., Pirosa, M. C., Salehi, M., Marques de Almeida, J., Passweg, J., Cavalli, F., Zucca, E., Gerber, B., Stussi, G., Gattei, V., Ghia, P., Gregor, M., Passamonti, F., Laurenti, Luca, Gaidano, G., Tedeschi, Alessandra, Rossi, Dario, Condoluci, A., Autore F., Merli M., Laurenti L. (ORCID:0000-0002-8327-1396), Tedeschi A., Rossi D., Forestieri, G., Terzi di Bergamo, L., Deodato, M., Frustaci, A. M., Moia, R., Deambrogi, C., Rasi, S., Autore, Francesco, Merli, Maria Clara, Mattarucchi, R., Fahrni, G., Scarfo', L., Gussetti, D., Bulian, P., Zanatta, A., Spina, V., Bruscaggin, A., Pini, K., Piffaretti, D., Pirosa, M. C., Salehi, M., Marques de Almeida, J., Passweg, J., Cavalli, F., Zucca, E., Gerber, B., Stussi, G., Gattei, V., Ghia, P., Gregor, M., Passamonti, F., Laurenti, Luca, Gaidano, G., Tedeschi, Alessandra, Rossi, Dario, Condoluci, A., Autore F., Merli M., Laurenti L. (ORCID:0000-0002-8327-1396), Tedeschi A., and Rossi D.

Abstract

NA

Published
2022

22. SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

Author

Pozzo, F, Bittolo, T, Tissino, E, Vit, F, Vendramini, E, Laurenti, L, D'Arena, G, Olivieri, J, Pozzato, G, Zaja, F, Chiarenza, A, Di Raimondo, F, Zucchetto, A, Bomben, R, Rossi, Fm, Del Poeta, G, Dal Bo, M, Gattei, V., Pozzo, F, Bittolo, T, Tissino, E, Vit, F, Vendramini, E, Laurenti, L, D'Arena, G, Olivieri, J, Pozzato, G, Zaja, F, Chiarenza, A, Di Raimondo, F, Zucchetto, A, Bomben, R, Rossi, Fm, Del Poeta, G, Dal Bo, M, and Gattei, V.

Subjects
Down-Regulation, Article, NOTCH1, immune system diseases, hemic and lymphatic diseases, Humans, CD20, Receptor, Notch1, Antigens, Chronic, neoplasms, CLL, SF3B1, Notch1, Leukemia, B-Cell, Antigens, CD20, Phosphoproteins, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic, Settore MED/15 - MALATTIE DEL SANGUE, embryonic structures, Mutation, cardiovascular system, RNA Splicing Factors, Receptor
Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a low CD20 expression, in part explained by an epigenetic-driven downregulation triggered by mutations of the NOTCH1 gene. In the present study, by taking advantage of a wide and well-characterized CLL cohort (n=537), we demonstrate that CD20 expression is downregulated in SF3B1-mutated CLL in an extent similar to NOTCH1-mutated CLL. In fact, SF3B1-mutated CLL cells show common features with NOTCH1-mutated CLL cells, including a gene expression profile enriched of NOTCH1-related gene sets and elevated expression of the active intracytoplasmic NOTCH1. Activation of the NOTCH1 signaling and down-regulation of surface CD20 in SF3B1-mutated CLL cells correlate with over-expression of an alternatively spliced form of DVL2, a component of the Wnt pathway and negative regulator of the NOTCH1 pathway. These findings are confirmed by separately analyzing the CD20-dim and CD20-bright cell fractions from SF3B1-mutated cases as well as by DVL2 knock-out experiments in CLL-like cell models. Altogether, the clinical and biological features that characterize NOTCH1-mutated CLL may also be recapitulated in SF3B1-mutated CLL, contributing to explain the poor prognosis of this CLL subset and providing the rationale for expanding novel agents-based therapies to SF3B1-mutated CLL.

Published
2020

23. 842P Secreted factors determine resistance to idelalisib in splenic marginal zone lymphoma (MZL) models

Author

Arribas, A.J., primary, Napoli, S., additional, Cascione, L., additional, Sartori, G., additional, Gaudio, E., additional, Tarantelli, C., additional, Mensah, A.A., additional, Spriano, F., additional, Zucchetto, A., additional, Rossi, F.M., additional, Rinaldi, A., additional, Jovic, S., additional, Stathis, A., additional, Stussi, G., additional, Gattei, V., additional, Brown, J.R., additional, Esteller, M., additional, Zucca, E., additional, Rossi, D., additional, and Bertoni, F., additional

Published
2021
Full Text
View/download PDF

24. COMBINED USE OF MINIMAL RESIDUAL DISEASE MONITORING AND FDG‐PET FOR OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL.

Author

Ferrero, S., Assanto, G. M., Durmo, R., Marcheselli, L., Mantoan, B., Pironti, M., Guerra, L., Boccomini, C., Puccini, B., Pulsoni, A., Pavone, V., Arcari, A., Califano, C., Castellino, C., Bari, A., Conconi, A., Dardanis, D., Chauvie, S., Gattei, V., and Del Giudice, I.

Subjects
FOLLICULAR lymphoma, POSITRON emission tomography, NON-Hodgkin's lymphoma
Abstract

B Discussion: b MRD analysis and PET scan are independent and complementary prognostic tools in FL: a MRD positivity in the two years after immuno-chemotherapy is predictive of POD24 and dismal PFS independently from the EoI PET result. This means that patients scoring PET- at EoI but showing a persistent or reappearing MRD+ signal during the following 24 months had a dismal PFS, superimposable to that of PET+ patients (Figure 1C). B Introduction: b In follicular lymphoma (FL), FDG-PET is routinely employed to evaluate response at the end of induction (EoI), while minimal residual disease (MRD) analysis is highly reliable in predicting relapse over the entire disease history. [Extracted from the article]

Published
2023
Full Text
View/download PDF

25. IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA

Author

Condoluci, A., primary, Terzi‐di‐Bergamo, L., additional, Forestieri, G., additional, Moia, R., additional, Deambrogi, C., additional, Deodato, M., additional, Frustaci, A. M., additional, Merli, M., additional, Mattarucchi, R., additional, Autore, F., additional, Fahrni, G., additional, Scarfò, L., additional, Gussetti, D., additional, Bulian, P., additional, Zanatta, A., additional, Spina, V., additional, Faderl, M. R., additional, Bruscaggin, A., additional, Pini, K., additional, Piffaretti, D., additional, Koch, R., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Passweg, J., additional, Cavalli, F., additional, Zucca, E., additional, Gerber, B., additional, Gillessen, S., additional, Stüssi, G., additional, Gattei, V., additional, Ghia, P., additional, Gregor, M., additional, Laurenti, L., additional, Passamonti, F., additional, Tedeschi, A., additional, Gaidano, G., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

26. ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY

Author

Terzi di Bergamo, L, primary, Forestieri, G, additional, Loh, J. W, additional, Singh, A, additional, Spina, V, additional, Zucchetto, A, additional, Condoluci, A, additional, Faderl, M, additional, Koch, R, additional, Bruscaggin, A, additional, Pini, K, additional, Wu, W, additional, Piffaretti, D, additional, Bittolo, T, additional, Tissino, E, additional, Paoli, L, additional, Deambrogi, C, additional, Frustaci, A. M, additional, Autore, F, additional, Merli, M, additional, Scarfò, L, additional, Rasi, S, additional, Passweg, J, additional, Moia, R, additional, Martines, C, additional, Ghia, P, additional, Cavalli, F, additional, Zucca, E, additional, Gerber, B, additional, Gillessen, S, additional, Stüssi, G, additional, Montillo, M, additional, Passamonti, F, additional, Gregor, M, additional, Laurenti, L, additional, Tedeschi, A, additional, Gaidano, G, additional, Efremov, D, additional, Gattei, V, additional, Khiabanian, H, additional, and Rossi, D, additional

Published
2021
Full Text
View/download PDF

27. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

Author

Luminari, S., primary, Galimberti, S., additional, Versari, A., additional, Tucci, A., additional, Boccomini, C., additional, Farina, L., additional, Zaja, F., additional, Marcheselli, L., additional, Ferrero, S., additional, Arcaini, L., additional, Pulsoni, A., additional, Musuraca, G., additional, Califano, C., additional, Merli, M., additional, Bari, A., additional, Conconi, A., additional, Giudice, I. del, additional, Re, F., additional, Stefani, P. M., additional, Usai, S. V., additional, Perrone, T., additional, Gini, G., additional, Falini, B., additional, Gattei, V., additional, Manni, M., additional, Ladetto, M., additional, Mannina, D., additional, and Federico, M., additional

Published
2021
Full Text
View/download PDF

28. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA

Author

Spina, V., primary, Pirosa, M. C., additional, Bruscaggin, A., additional, Condoluci, A., additional, Pini, K., additional, Forestieri, G., additional, Zangrilli, I., additional, di Trani, M., additional, Kurlapski, M., additional, Moccia, A., additional, Moia, R., additional, Bulian, P., additional, Annunziata, S., additional, Borsatti, E., additional, Rodari, M., additional, Romanowicz, G., additional, Sacchetti, G. M., additional, Faderl, M., additional, Koch, R., additional, Piffaretti, D., additional, Terzi di Bergamo, L., additional, Stasia, A., additional, Cittone, M., additional, Chauvie, S., additional, Stüssi, G., additional, Gerber, B., additional, Stathis, A., additional, Sommer, S. Gillessen, additional, Cavalli, F., additional, Zucca, E., additional, Gattei, V., additional, Zaucha, J. M., additional, Pinto, A., additional, Gaidano, G., additional, Carlo‐Stella, C., additional, Hohaus, S., additional, Ceriani, L., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

29. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA

Author

Pulsoni, A., primary, Tosti, M. E., additional, Ferrero, S., additional, Luminari, S., additional, Dondi, A., additional, Liberati, A. M., additional, Cenfra, N., additional, Renzi, D., additional, Zanni, M., additional, Boccomini, C., additional, Ferreri, A. J., additional, Rattotti, S., additional, Zilioli, V. R., additional, Bernuzzi, P., additional, Bolis, S., additional, Musuraca, G., additional, Nassi, L., additional, Perrone, T., additional, Stelitano, C., additional, Anastasia, A., additional, Corradini, P., additional, Partesotti, G., additional, Re, F., additional, Cencini, E., additional, Mannarella, C., additional, Mannina, D., additional, Molinari, A. L., additional, Tani, M., additional, Annechini, G., additional, Assanto, G. M., additional, Grapulin, L., additional, Guarini, A., additional, Cavalli, M., additional, De Novi, L. A., additional, Ciabatti, E., additional, Mantoan, B., additional, Della Starza, I., additional, Arcaini, L., additional, Ricardi, U., additional, Gattei, V., additional, Galimberti, S., additional, Ladetto, M., additional, Foà, R., additional, and Del Giudice, I., additional

Published
2021
Full Text
View/download PDF

30. Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials

Author

Morabito, F., Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, F. M., Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Cassin, R., D'Arrigo, G., Galimberti, S., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, P., Menichini, P., Olivieri, J., Cutrona, G., Rossi, D., Cuneo, A., Di Raimondo, F., Gaidano, G., Polliack, A., Trentin, L., Foa, R., Ferrarini, M., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., Gentile M., Morabito, F., Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, F. M., Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Cassin, R., D'Arrigo, G., Galimberti, S., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, P., Menichini, P., Olivieri, J., Cutrona, G., Rossi, D., Cuneo, A., Di Raimondo, F., Gaidano, G., Polliack, A., Trentin, L., Foa, R., Ferrarini, M., Gattei, V., Gentile, M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., and Gentile M.

Abstract

n/a

Published
2021

31. Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

Author

Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Mendicino, F., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, Paolo, Menichini, P., Cutrona, G., Jaksic, O., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., Gentile M., Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Vigna, E., Martino, E. A., Mendicino, F., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Monti, Paolo, Menichini, P., Cutrona, G., Jaksic, O., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Monti P. (ORCID:0000-0002-2586-1881), Rossi D., Foa R., and Gentile M.

Abstract

Objectives: To compare the capacity of ibrutinib (IB) and idelalisib-rituximab (IDELA-R) of prolonging overall survival (OS) as in CLL patients, previously treated with chemotherapy only. Methods: A real-life cohort of 675 cases has been identified and investigated in the database of the groups participating in the study. Results: At an unadjusted univariate analysis, a significant death risk reduction was observed favoring IB (IDELA-R vs IB HR = 0.5, 95% CI = 0.36-0.71) although with some limitations due to the non-randomized and retrospective nature of the study and to the lower number of patients in the IDELA-R group (112 cases) related to the current prescribing practice. To overcome the potential problem of confounding by indication, we adjusted the association between the type of therapy and mortality for all variables significantly associated with OS at Cox univariate analysis. Furthermore, those variables, differently distributed between the two study groups, were introduced into the multivariate Cox model to improve the effectiveness of the analysis. By introducing all these variables into the multiple Cox regression model, we confirmed the protective effect of IB vs IDELA-R (HR = 0.67, 95% CI = 0.45-0.98, P =.04) independent of potential confounders. Conclusions: Although our analysis presents some constraints, that is, the unavailability of additional potential confounders, and the retrospective nature of the study, this observation may be of help for the daily clinical practice, particularly in the absence of randomized trials comparing the two schedules.

Published
2021

32. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report

Author

Cuneo, A., Rigolin, G. M., Coscia, M., Quaresmini, G., Scarfo, L., Mauro, F. R., Motta, M., Quaglia, F. M., Trentin, L., Ferrario, Alberto Alfredo, Laurenti, Luca, Reda, G., Ferrari, A., Pietrasanta, D., Sportoletti, P., Re, F., De Paoli, L., Foglietta, M., Giordano, A., Marchetti, M., Farina, L., Del Poeta, G., Varettoni, M., Chiurazzi, F., Marasca, R., Malerba, L., Ibatici, A., Tisi, Maria Chiara, Stefoni, V., Leone, M., Barate, C., Olivieri, J., Murru, R., Gentile, Marino, Sanna, A., Gozzetti, A., Gattei, V., Gottardi, D., Derenzini, E., Levato, L., Orsucci, L., Penna, G., Chiarenza, A., Foa, Robin, Ferrario A., Laurenti L. (ORCID:0000-0002-8327-1396), Tisi M. C., Gentile M., Foa R., Cuneo, A., Rigolin, G. M., Coscia, M., Quaresmini, G., Scarfo, L., Mauro, F. R., Motta, M., Quaglia, F. M., Trentin, L., Ferrario, Alberto Alfredo, Laurenti, Luca, Reda, G., Ferrari, A., Pietrasanta, D., Sportoletti, P., Re, F., De Paoli, L., Foglietta, M., Giordano, A., Marchetti, M., Farina, L., Del Poeta, G., Varettoni, M., Chiurazzi, F., Marasca, R., Malerba, L., Ibatici, A., Tisi, Maria Chiara, Stefoni, V., Leone, M., Barate, C., Olivieri, J., Murru, R., Gentile, Marino, Sanna, A., Gozzetti, A., Gattei, V., Gottardi, D., Derenzini, E., Levato, L., Orsucci, L., Penna, G., Chiarenza, A., Foa, Robin, Ferrario A., Laurenti L. (ORCID:0000-0002-8327-1396), Tisi M. C., Gentile M., and Foa R.

Abstract

n/a

Published
2021

33. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Author

Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Vigna, E., Martino, E. A., Mendicino, F., Botta, C., Caracciolo, D., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., Gentile M., Morabito, Francesco, Tripepi, G., Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Vigna, E., Martino, E. A., Mendicino, F., Botta, C., Caracciolo, D., Cassin, R., D'Arrigo, G., Galimberti, Sofia, Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Neri, A., Fronza, G., Cutrona, G., Rossi, Dario, Di Raimondo, F., Cuneo, A., Gaidano, G., Polliack, A., Trentin, L., Foa, Robin, Ferrarini, M., Gattei, V., Gentile, Marino, Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Galimberti S., Rossi D., Foa R., and Gentile M.

Abstract

n/a

Published
2021

34. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Marino, Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Recchia, A. G., Varettoni, M., Murru, R., Chiarenza, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Fraticelli, V., Vigna, E., Botta, C., Tripepi, G., Arrigo, G. D., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Rigolin, G. M., Rossi, Dario, Di Raimondo, F., Gaidano, G., Polliack, A., Cuneo, A., Foa, Robin, Gattei, V., Gentile M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Rossi D., Foa R., Gentile, Marino, Morabito, Francesco, Del Poeta, G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, Luca, Coscia, M., Herishanu, Y., Recchia, A. G., Varettoni, M., Murru, R., Chiarenza, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Fraticelli, V., Vigna, E., Botta, C., Tripepi, G., Arrigo, G. D., Rago, A., Angeletti, I., Biagi, A., Del Giudice, I., Bomben, R., Rigolin, G. M., Rossi, Dario, Di Raimondo, F., Gaidano, G., Polliack, A., Cuneo, A., Foa, Robin, Gattei, V., Gentile M., Morabito F., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Rossi D., and Foa R.

Abstract

N/A

Published
2021

39. HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia

Author

Griggio, V., Vitale, C., Todaro, M., Riganti, C., Kopecka, J., Salvetti, C., Bomben, R., M. D., Bo, Magliulo, D., Rossi, D., Pozzato, G., Bonello, L., Marchetti, M., Omede, P., Kodipad, A. A., Laurenti, L., Poeta, G. D., Mauro, F. R., Bernardi, R., Zenz, T., Gattei, V., Gaidano, G., Foa, R., Massaia, M., Boccadoro, M., and Coscia, M.

Subjects
Animals, Humans, Hypoxia-Inducible Factor 1, alpha Subunit, Mice, Phosphatidylinositol 3-Kinases, Tumor Microenvironment, Tumor Suppressor Protein p53, Von Hippel-Lindau Tumor Suppressor Protein, Leukemia, Lymphocytic, Chronic, B-Cell
Published
2020

42. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Author

Gentile, Marino, Martino, E. A., Visentin, A., Coscia, M., Reda, G., Sportoletti, P., Mauro, F. R., Laurenti, Luca, Varettoni, M., Murru, R., Chiarenza, A., Vigna, E., Mendicino, F., Lucia, E., Bossio, S., Recchia, A. G., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Vitale, C., Tripepi, G., D'Arrigo, G., Angeletti, I., Bomben, R., Neri, A., Cutrona, G., Fronza, G., Di Raimondo, F., Gaidano, G., Cuneo, A., Foa, Robin, Ferrarini, M., Trentin, L., Gattei, V., Morabito, Francesco, Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Foa R., Morabito F., Gentile, Marino, Martino, E. A., Visentin, A., Coscia, M., Reda, G., Sportoletti, P., Mauro, F. R., Laurenti, Luca, Varettoni, M., Murru, R., Chiarenza, A., Vigna, E., Mendicino, F., Lucia, E., Bossio, S., Recchia, A. G., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., Rossi, Federica Maria, Zucchetto, A., Al-Janazreh, H., Vitale, C., Tripepi, G., D'Arrigo, G., Angeletti, I., Bomben, R., Neri, A., Cutrona, G., Fronza, G., Di Raimondo, F., Gaidano, G., Cuneo, A., Foa, Robin, Ferrarini, M., Trentin, L., Gattei, V., Morabito, Francesco, Gentile M., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Foa R., and Morabito F.

Abstract

N/a

Published
2020

43. SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation

Author

Pozzo, F., Bittolo, T., Tissino, E., Vit, F., Vendramini, E., Laurenti, Luca, D'Arena, G., Olivieri, J., Pozzato, G., Zaja, F., Chiarenza, A., Di Raimondo, F., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Del Poeta, G., Dal Bo, M., Gattei, V., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi F. M., Pozzo, F., Bittolo, T., Tissino, E., Vit, F., Vendramini, E., Laurenti, Luca, D'Arena, G., Olivieri, J., Pozzato, G., Zaja, F., Chiarenza, A., Di Raimondo, F., Zucchetto, A., Bomben, R., Rossi, Federica Maria, Del Poeta, G., Dal Bo, M., Gattei, V., Laurenti L. (ORCID:0000-0002-8327-1396), and Rossi F. M.

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a low CD20 expression, in part explained by an epigenetic-driven downregulation triggered by mutations of the NOTCH1 gene. In the present study, by taking advantage of a wide and well-characterized CLL cohort (n=537), we demonstrate that CD20 expression is downregulated in SF3B1-mutated CLL in an extent similar to NOTCH1-mutated CLL. In fact, SF3B1-mutated CLL cells show common features with NOTCH1-mutated CLL cells, including a gene expression profile enriched of NOTCH1-related gene sets and elevated expression of the active intracytoplasmic NOTCH1. Activation of the NOTCH1 signaling and down-regulation of surface CD20 in SF3B1-mutated CLL cells correlate with over-expression of an alternatively spliced form of DVL2, a component of the Wnt pathway and negative regulator of the NOTCH1 pathway. These findings are confirmed by separately analyzing the CD20-dim and CD20-bright cell fractions from SF3B1-mutated cases as well as by DVL2 knock-out experiments in CLL-like cell models. Altogether, the clinical and biological features that characterize NOTCH1-mutated CLL may also be recapitulated in SF3B1-mutated CLL, contributing to explain the poor prognosis of this CLL subset and providing the rationale for expanding novel agents-based therapies to SF3B1-mutated CLL.

Published
2020

44. CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression

Author

Tissino, E., Pozzo, F., Benedetti, D., Caldana, C., Bittolo, T., Rossi, Federica Maria, Bomben, R., Nanni, P., Chivilo, H., Cattarossi, I., Zaina, Elisabetta, Norris, K., Polesel, J., Gentile, Marino, Tripepi, G., Moia, R., Santinelli, E., Innocenti, Idanna, Olivieri, J., D'Arena, G., Laurenti, Luca, Zaja, F., Pozzato, G., Chiarenza, A., Di Raimondo, F., Rossi, Dario, Pepper, C., Hartmann, T. N., Gaidano, G., Del Poeta, G., Gattei, V., Zucchetto, A., Rossi F. M., Zaina E., Gentile M., Innocenti I., Laurenti L. (ORCID:0000-0002-8327-1396), Rossi D., Tissino, E., Pozzo, F., Benedetti, D., Caldana, C., Bittolo, T., Rossi, Federica Maria, Bomben, R., Nanni, P., Chivilo, H., Cattarossi, I., Zaina, Elisabetta, Norris, K., Polesel, J., Gentile, Marino, Tripepi, G., Moia, R., Santinelli, E., Innocenti, Idanna, Olivieri, J., D'Arena, G., Laurenti, Luca, Zaja, F., Pozzato, G., Chiarenza, A., Di Raimondo, F., Rossi, Dario, Pepper, C., Hartmann, T. N., Gaidano, G., Del Poeta, G., Gattei, V., Zucchetto, A., Rossi F. M., Zaina E., Gentile M., Innocenti I., Laurenti L. (ORCID:0000-0002-8327-1396), and Rossi D.

Abstract

CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d expression. In the present study, we analyzed a cohort of 1630 CLL samples and identified the presence of ∼20% of CLL cases (n 5 313) characterized by a bimodal expression of CD49d, that is, concomitant presence of a CD49d1 subpopulation and a CD49d2 subpopulation. At variance with the highly stable CD49d expression observed in CLL patients with a homogeneous pattern of CD49d expression, CD49d bimodal CLL showed a higher level of variability in sequential samples, and an increase in the CD49d1 subpopulation over time after therapy. The CD49d1 subpopulation from CD49d bimodal CLL displayed higher levels of proliferation compared with the CD49d2 cells; and was more highly represented in the bone marrow compared with peripheral blood (PB), and in PB CLL subsets expressing the CXCR4dim/CD5bright phenotype, known to be enriched in proliferative cells. From a clinical standpoint, CLL patients with CD49d bimodal expression, regardless of whether the CD49d1 subpopulation exceeded the 30% cutoff or not, experienced clinical behavior similar to CD49d1 CLL, both in chemoimmunotherapy (n 5 1522) and in ibrutinib (n 5 158) settings. Altogether, these results suggest that CD49d can drive disease progression in CLL, and that the pattern of CD49d expression should also be considered to improve the prognostic impact of this biomarker in CLL.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results